Precigen Inc · Q4 2021 earnings

Briefing

Precigen's financial performance in Q4 2021 was reported, featuring increased revenues driven by Trans Ova and Exemplar, alongside a reduced net loss compared to the previous year.

Precigen reported a net loss from continuing operations of $25.0 million, or $(0.13) per share, for Q4 2021, compared to a net loss of $39.7 million, or $(0.22) per share, for Q4 2020. Total revenues increased by $4.9 million, or 25%, primarily driven by product and service revenues from Trans Ova and Exemplar.

• R&D expenses increased by $2.3 million, or 22%, due to increased personnel and contract research organization costs.
• SG&A expenses decreased by $13.3 million, or 44%, primarily due to a noncash loss on a settlement agreement in the prior year.
• Total revenues increased by $4.9 million, or 25%, driven by Trans Ova and Exemplar.
• Net loss from continuing operations improved to $25.0 million, or $(0.13) per share, compared to $39.7 million, or $(0.22) per share, in the prior year's fourth quarter.

Headline financials

Revenue & EPS history

Precigen will advance assets with the most promising paths to licensure and will continue to focus on strengthening its financial position by continuing to ensure operational efficiency while seeking strategic non-dilutive funding opportunities where appropriate.